- Home
- ALXO vs LICY Comparison
ALXO vs LICY Comparison
Compare ALXO & LICY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- LICY
- Stock Information
- Founded
- ALXO 2015
- LICY 2016
- Country
- ALXO United States
- LICY Canada
- Employees
- ALXO N/A
- LICY N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- LICY Environmental Services
- Sector
- ALXO Health Care
- LICY Industrials
- Exchange
- ALXO Nasdaq
- LICY Nasdaq
- Market Cap
- ALXO 81.1M
- LICY 83.8M
- IPO Year
- ALXO 2020
- LICY N/A
- Fundamental
- Price
- ALXO $1.41
- LICY $2.14
- Analyst Decision
- ALXO Strong Buy
- LICY Hold
- Analyst Count
- ALXO 6
- LICY 2
- Target Price
- ALXO $14.20
- LICY $4.13
- AVG Volume (30 Days)
- ALXO 886.3K
- LICY 2.5M
- Earning Date
- ALXO 11-07-2024
- LICY 11-07-2024
- Dividend Yield
- ALXO N/A
- LICY N/A
- EPS Growth
- ALXO N/A
- LICY N/A
- EPS
- ALXO N/A
- LICY N/A
- Revenue
- ALXO N/A
- LICY $27,400,000.00
- Revenue This Year
- ALXO N/A
- LICY $48.13
- Revenue Next Year
- ALXO N/A
- LICY $18.15
- P/E Ratio
- ALXO N/A
- LICY N/A
- Revenue Growth
- ALXO N/A
- LICY N/A
- 52 Week Low
- ALXO $1.19
- LICY $1.22
- 52 Week High
- ALXO $17.83
- LICY $15.36
- Technical
- Relative Strength Index (RSI)
- ALXO 47.30
- LICY 44.54
- Support Level
- ALXO $1.19
- LICY $2.05
- Resistance Level
- ALXO $1.63
- LICY $2.38
- Average True Range (ATR)
- ALXO 0.11
- LICY 0.54
- MACD
- ALXO 0.01
- LICY -0.10
- Stochastic Oscillator
- ALXO 50.00
- LICY 4.70
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About LICY Li-Cycle Holdings Corp.
Li-Cycle Holdings Corp is a lithium-ion battery resource recovery and lithium-ion battery recycler. The company's proprietary process Spoke and Hub recycling process is designed at its Spokes, to process battery manufacturing scrap and end-of-life batteries to produce black mass and other intermediate products, and at its Hubs, to process black mass to recover raw materials, including but not limited to lithium carbonate, cobalt sulphate, and nickel sulphate.